Issue 18, 2015

Molecular modeling studies of dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase using 3D-QSAR, Topomer CoMFA and molecular docking simulations

Abstract

The human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is generally regarded as a target for the treatment of acquired immune deficiency syndrome (AIDS). Non-nucleoside RT inhibitors (commonly known as NNRTIs) are currently being used in the treatment of HIV-1 infections. In this work, a series of NNRTIs were studied using a combination of molecular modeling techniques including three-dimensional quantitative structure–activity relationship (3D-QSAR), Topomer CoMFA and molecular docking simulations. The best optimum comparative molecule field analysis (CoMFA) model yielded a leave-one-out correlation coefficient (q2) and a non-cross-validated correlation coefficient (r2) of 0.636 and 0.993, respectively. The respective q2 and r2 of the best comparative molecular similarity indices analysis (CoMSIA) model were 0.655 and 0.998. The models were validated by test sets, and predicted correlation coefficients (rpred2) of 0.907 and 0.886 obtained from the CoMFA and CoMSIA models, thus judging the robustness of the model. The analysis of Topomer CoMFA obtained a q2 of 0.546 and a rpred2 value of 0.718 which suggested the model had a good predictive ability (q2 > 0.2). The results indicated the steric, hydrophobic and electrostatic fields play key roles in the models. Molecular docking elucidated the conformations of the compounds and key amino acid residues at the docking pocket of RT protein.

Graphical abstract: Molecular modeling studies of dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase using 3D-QSAR, Topomer CoMFA and molecular docking simulations

Article information

Article type
Paper
Submitted
28 Nov 2014
Accepted
21 Jan 2015
First published
21 Jan 2015

RSC Adv., 2015,5, 13754-13761

Author version available

Molecular modeling studies of dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase using 3D-QSAR, Topomer CoMFA and molecular docking simulations

M. Dong and Y. Ren, RSC Adv., 2015, 5, 13754 DOI: 10.1039/C4RA15397A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements